Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
Identifieur interne : 002076 ( Main/Merge ); précédent : 002075; suivant : 002077Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
Auteurs : Rodger J. Elble [États-Unis] ; Oksana Suchowersky [Canada] ; Stephanie Shaftman [Canada, États-Unis] ; William J. Weiner [États-Unis] ; Peng Huang [États-Unis] ; Barbara Tilley [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-06-15.
English descriptors
- KwdEn :
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuroprotective Agents (therapeutic use), Parkinson Disease (drug therapy), Parkinson Disease (psychology), Parkinson's disease, Randomized Controlled Trials as Topic, Severity of Illness Index, Statistics, Nonparametric, Treatment Outcome, Ubiquinone (therapeutic use), Unified Parkinson's Disease Rating Scale, bias, clinical trial.
- MESH :
- chemical , therapeutic use : Neuroprotective Agents, Ubiquinone.
- drug therapy : Parkinson Disease.
- psychology : Parkinson Disease.
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Randomized Controlled Trials as Topic, Severity of Illness Index, Statistics, Nonparametric, Treatment Outcome.
Abstract
We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double‐blind placebo‐controlled futility trial of coenzyme Q10 and GPI‐1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment. © 2010 Movement Disorder Society
Url:
- https://api.istex.fr/document/7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891220
DOI: 10.1002/mds.22997
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001600
- to stream Istex, to step Curation: 001600
- to stream Istex, to step Checkpoint: 000919
- to stream Pmc, to step Corpus: 000082
- to stream Pmc, to step Curation: 000082
- to stream Pmc, to step Checkpoint: 000338
- to stream PubMed, to step Corpus: 001991
- to stream PubMed, to step Curation: 001991
- to stream PubMed, to step Checkpoint: 001836
- to stream Ncbi, to step Merge: 002A11
- to stream Ncbi, to step Curation: 002A11
- to stream Ncbi, to step Checkpoint: 002A11
Links to Exploration step
ISTEX:7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J." last="Elble">Rodger J. Elble</name></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22997</idno><idno type="url">https://api.istex.fr/document/7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001600</idno><idno type="wicri:Area/Istex/Curation">001600</idno><idno type="wicri:Area/Istex/Checkpoint">000919</idno><idno type="wicri:doubleKey">0885-3185:2010:Elble R:impact:of:belief</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891220</idno><idno type="RBID">PMC:2891220</idno><idno type="wicri:Area/Pmc/Corpus">000082</idno><idno type="wicri:Area/Pmc/Curation">000082</idno><idno type="wicri:Area/Pmc/Checkpoint">000338</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">001991</idno><idno type="wicri:Area/PubMed/Curation">001991</idno><idno type="wicri:Area/PubMed/Checkpoint">001836</idno><idno type="wicri:Area/Ncbi/Merge">002A11</idno><idno type="wicri:Area/Ncbi/Curation">002A11</idno><idno type="wicri:Area/Ncbi/Checkpoint">002A11</idno><idno type="wicri:doubleKey">0885-3185:2010:Elble R:impact:of:belief</idno><idno type="wicri:Area/Main/Merge">002076</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J." last="Elble">Rodger J. Elble</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medical Genetics, University of Calgary, Calgary, Alberta</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Oncology, Johns Hopkins University, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Biostatistics, University of Texas Health Science Center School of Public Health, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-06-15">2010-06-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1082">1082</biblScope><biblScope unit="page" to="1086">1086</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422</idno><idno type="DOI">10.1002/mds.22997</idno><idno type="ArticleID">MDS22997</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Parkinson's disease</term><term>Randomized Controlled Trials as Topic</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term><term>Ubiquinone (therapeutic use)</term><term>Unified Parkinson's Disease Rating Scale</term><term>bias</term><term>clinical trial</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term><term>Ubiquinone</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Randomized Controlled Trials as Topic</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double‐blind placebo‐controlled futility trial of coenzyme Q10 and GPI‐1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment. © 2010 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.22997"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J." last="Elble">Rodger J. Elble</name></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22997</idno><idno type="url">https://api.istex.fr/document/7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001600</idno><idno type="wicri:Area/Istex/Curation">001600</idno><idno type="wicri:Area/Istex/Checkpoint">000919</idno><idno type="wicri:doubleKey">0885-3185:2010:Elble R:impact:of:belief</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J." last="Elble">Rodger J. Elble</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medical Genetics, University of Calgary, Calgary, Alberta</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Oncology, Johns Hopkins University, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Biostatistics, University of Texas Health Science Center School of Public Health, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-06-15">2010-06-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1082">1082</biblScope><biblScope unit="page" to="1086">1086</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422</idno><idno type="DOI">10.1002/mds.22997</idno><idno type="ArticleID">MDS22997</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>Unified Parkinson's Disease Rating Scale</term><term>bias</term><term>clinical trial</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double‐blind placebo‐controlled futility trial of coenzyme Q10 and GPI‐1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment. © 2010 Movement Disorder Society</div></front></TEI></ISTEX><PMC><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J." last="Elble">Rodger J. Elble</name><affiliation><nlm:aff id="A1"> Department of Neurology, Southern Illinois University School of Medicine</nlm:aff><wicri:noCountry code="subfield">Southern Illinois University School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation wicri:level="4"><nlm:aff id="A2"> Departments of Medical Genetics and Clinical Neurosciences, University of Calgary</nlm:aff><country>Canada</country><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName><orgName type="university">Université de Calgary</orgName></affiliation></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name><affiliation><nlm:aff id="A3"> Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina</nlm:aff><wicri:noCountry code="subfield">Medical University of South Carolina</wicri:noCountry></affiliation></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name><affiliation><nlm:aff id="A4"> Department of Neurology, University of Maryland School of Medicine</nlm:aff><wicri:noCountry code="subfield">University of Maryland School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name><affiliation><nlm:aff id="A5"> Department of Oncology, Johns Hopkins University</nlm:aff><wicri:noCountry code="subfield">Johns Hopkins University</wicri:noCountry></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation><nlm:aff id="A6"> University of Texas Health Science Center School of Public Health at Houston</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20131372</idno><idno type="pmc">2891220</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891220</idno><idno type="RBID">PMC:2891220</idno><idno type="doi">10.1002/mds.22997</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">000082</idno><idno type="wicri:Area/Pmc/Curation">000082</idno><idno type="wicri:Area/Pmc/Checkpoint">000338</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">001991</idno><idno type="wicri:Area/PubMed/Curation">001991</idno><idno type="wicri:Area/PubMed/Checkpoint">001836</idno><idno type="wicri:Area/Ncbi/Merge">002A11</idno><idno type="wicri:Area/Ncbi/Curation">002A11</idno><idno type="wicri:Area/Ncbi/Checkpoint">002A11</idno><idno type="wicri:doubleKey">0885-3185:2010:Elble R:impact:of:belief</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J." last="Elble">Rodger J. Elble</name><affiliation><nlm:aff id="A1"> Department of Neurology, Southern Illinois University School of Medicine</nlm:aff><wicri:noCountry code="subfield">Southern Illinois University School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation wicri:level="4"><nlm:aff id="A2"> Departments of Medical Genetics and Clinical Neurosciences, University of Calgary</nlm:aff><country>Canada</country><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName><orgName type="university">Université de Calgary</orgName></affiliation></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name><affiliation><nlm:aff id="A3"> Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina</nlm:aff><wicri:noCountry code="subfield">Medical University of South Carolina</wicri:noCountry></affiliation></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name><affiliation><nlm:aff id="A4"> Department of Neurology, University of Maryland School of Medicine</nlm:aff><wicri:noCountry code="subfield">University of Maryland School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name><affiliation><nlm:aff id="A5"> Department of Oncology, Johns Hopkins University</nlm:aff><wicri:noCountry code="subfield">Johns Hopkins University</wicri:noCountry></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation><nlm:aff id="A6"> University of Texas Health Science Center School of Public Health at Houston</nlm:aff></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Randomized Controlled Trials as Topic</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term><term>Ubiquinone (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term><term>Ubiquinone</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Randomized Controlled Trials as Topic</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">We explored the hypotheses that an investigator’s belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of Parkinson patients with the Unified Parkinson Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q<sub>10</sub> and GPI-1485. We found the investigators’ level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.</p></div></front></TEI></PMC></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002076 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002076 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422
|texte= Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |